Last reviewed · How we verify
Aspirin single antiplatelet therapy
Aspirin single antiplatelet therapy is a Small molecule drug developed by Yonsei University. It is currently in Phase 1 development.
At a glance
| Generic name | Aspirin single antiplatelet therapy |
|---|---|
| Sponsor | Yonsei University |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Total
- Stroke Progression
- Epistaxis
- Haematuria
- Rectal haemorrhage
- Catheter site haematoma
- Contusion
- Gingival bleeding
- Gastrointestinal haemorrhage
- Haematochezia
- Catheter site haemorrhage
- Laceration
Key clinical trials
- OPTIA-AF Trial: Rhythm-Guided Antithrombotic Strategy After AF Ablation (PHASE4)
- PFO Closure, Oral Anticoagulants or Antiplatelet Therapy After PFO-associated Stroke in Patients Aged 60 to 80 Years (PHASE3)
- Aspirin-free Strategy With Ticagrelor in Patients With a Myocardial Infarction Treated Medically Alone (PHASE3)
- STrategies for Antithrombotic tReatment Following Transcatheter Edge-to-Edge Repair in Patients Without an Indication for Oral Anticoagulant (PHASE4)
- Testing a New Treatment Strategy to Improve Secondary Stroke Prevention for Older Adults: The STROKE75+ Trial (PHASE3)
- ATILA Project: Aspirin Versus Tirofiban in Endovascular Treatment for Patients With Acute Ischemic Stroke Due to Tandem Lesion (PHASE4)
- Stent Implantation Versus Medical Therapy for Idiopathic IntracraniaL Hypertension (SIMPLE) (PHASE3)
- HR-MRI-Directed Tirofiban Therapy for Late-Window Acute Ischemic Stroke (TIAN) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Aspirin single antiplatelet therapy CI brief — competitive landscape report
- Aspirin single antiplatelet therapy updates RSS · CI watch RSS
- Yonsei University portfolio CI
Frequently asked questions about Aspirin single antiplatelet therapy
What is Aspirin single antiplatelet therapy?
Aspirin single antiplatelet therapy is a Small molecule drug developed by Yonsei University.
Who makes Aspirin single antiplatelet therapy?
Aspirin single antiplatelet therapy is developed by Yonsei University (see full Yonsei University pipeline at /company/yonsei-university).
What development phase is Aspirin single antiplatelet therapy in?
Aspirin single antiplatelet therapy is in Phase 1.
What are the side effects of Aspirin single antiplatelet therapy?
Common side effects of Aspirin single antiplatelet therapy include Total, Stroke Progression, Epistaxis, Haematuria, Rectal haemorrhage, Catheter site haematoma.